The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 8053183 B1

PDF
Full Text
Expired
Date of Patent:
Nov. 08, 2011

Filed:

Jul. 26, 2006
Applicants:

Yusuke Nakamura, Bunkyo-ku, JP;

Yataro Daigo, Bunkyo-ku, JP;

Shuichi Nakatsuru, Kawasaki, JP;

Inventors:

Yusuke Nakamura, Bunkyo-ku, JP;

Yataro Daigo, Bunkyo-ku, JP;

Shuichi Nakatsuru, Kawasaki, JP;

Assignee:

Oncotherapy Science, Inc., Kawasaki-Shi, Kanagawa, JP;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C12Q 1/68 (2006.01); C12M 1/34 (2006.01); C12M 3/00 (2006.01); C12N 5/00 (2006.01); C12N 5/02 (2006.01); A61K 48/00 (2006.01); C07H 21/02 (2006.01);
U.S. Cl.
CPC ...
Abstract

In order to identify the molecules involved in esophageal carcinogenesis and those to be useful for diagnostic markers as well as targets for new drugs and immunotherapy, a cDNA microarray representing 32,256 genes was constructed to analyze the expression profiles of 19 esophageal squamous-cell carcinomas (ESCCS) purified by laser-capture microdissection. a detailed genome-wide database for sets of genes that are significantly up- or down-regulated in esophageal cancer is disclosed herein. these genes find use in the development of therapeutic drugs or immunotherapy as well as tumor markers. additionally, genes associated with lymph-node metastasis and post-surgery recurrence are disclosed herein. among the candidate molecular target genes, ECT2 and CDC45L and DKK1 are further characterized. treatment of ESCC cells with small interfering RNAs (siRNAs) of ECT2 or CDC45L suppressed growth of the cancer cells. Thus, the data herein provide valuable information for identifying diagnostic systems and therapeutic target molecules for esophageal cancer.


Find Patent Forward Citations

Loading…